» Articles » PMID: 40006673

Revolutionizing Nanovaccines: A New Era of Immunization

Overview
Date 2025 Feb 26
PMID 40006673
Authors
Affiliations
Soon will be listed here.
Abstract

Infectious diseases continue to pose a significant global health threat. To combat these challenges, innovative vaccine technologies are urgently needed. Nanoparticles (NPs) have unique properties and have emerged as a promising platform for developing next-generation vaccines. Nanoparticles are revolutionizing the field of vaccine development, offering a new era of immunization. They allow the creation of more effective, stable, and easily deliverable vaccines. Various types of NPs, including lipid, polymeric, metal, and virus-like particles, can be employed to encapsulate and deliver vaccine components, such as mRNA or protein antigens. These NPs protect antigens from degradation, target them to specific immune cells, and enhance antigen presentation, leading to robust and durable immune responses. Additionally, NPs can simultaneously deliver multiple vaccine components, including antigens, and adjuvants, in a single formulation, simplifying vaccine production and administration. Nanovaccines offer a promising approach to combat food- and water-borne bacterial diseases, surpassing traditional formulations. Further research is needed to address the global burden of these infections. This review highlights the potential of NPs to revolutionize vaccine platforms. We explore their mechanisms of action, current applications, and emerging trends. The review discusses the limitations of nanovaccines, innovative solutions and the potential role of artificial intelligence in developing more effective and accessible nanovaccines to combat infectious diseases.

References
1.
Xiang D, Zheng Y, Duan W, Li X, Yin J, Shigdar S . Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. Int J Nanomedicine. 2013; 8:4103-13. PMC: 3817021. DOI: 10.2147/IJN.S53622. View

2.
Topalidou X, Kalergis A, Papazisis G . Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. Pathogens. 2023; 12(10). PMC: 10609699. DOI: 10.3390/pathogens12101259. View

3.
Zhang D, Wang G, Yu X, Wei T, Farbiak L, Johnson L . Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol. 2022; 17(7):777-787. PMC: 9931497. DOI: 10.1038/s41565-022-01122-3. View

4.
Zhang B, Cavallaro A, Mody K, Zhang J, Deringer J, Brown W . Nanoparticle-Based Delivery of Anaplasma marginale Membrane Proteins; VirB9-1 and VirB10 Produced in the Pichia pastoris Expression System. Nanomaterials (Basel). 2017; 6(11). PMC: 5245741. DOI: 10.3390/nano6110201. View

5.
Lamb Y . BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021; 81(4):495-501. PMC: 7938284. DOI: 10.1007/s40265-021-01480-7. View